




SHIELD

Innovative multiplex immunoassays and AI for comprehensive early detection and monitoring of high-risk individuals with pancreatic cancer

Our mission

SHIELD is developing a simple blood test for early detection of pancreatic cancer. By focusing on people with elevated genetic risk, it aims to reduce late-stage diagnoses and increase Europe's five-year survival rate to 30% by 2035.



Detection

Early detection for high-risk individuals enables timely diagnosis.

Diagnostics

A cost-effective blood test for fast, affordable, and accurate diagnosis.

Impact

Fewer late diagnoses lead to earlier treatments and reduce overall mortality.



The Consortium



Learn more about Shield:

missionshield.eu

info@missionshield.eu

mastodon.social/@MissionSHIELD

[@SHIELD project](https://www.linkedin.com/company/shield-project)



Co-funded by the European Union



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Federal Department of Economic Affairs,
Education and Research EAER
State Secretariat for Education,
Research and Innovation SERI